Navigation Links
New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
Date:5/1/2012

CAESAREA, Israel, May 1, 2012 /PRNewswire/ --

CardioDex announces initial commercial use of a groundbreaking femoral access site closure device. Recent data from commercial use of the device on 41 patients at St Marien Hospital in Siegen Germany showed 100% success rate and no complications. "We are very excited about these new data that demonstrates that this device provides a viable treatment for a major unmet medical need due to the increasing use worldwide of percutaneous femoral access and the subsequent high rate of complications seen" said Dr. Hans Peter Hobbach, Deputy Chief of St Marien Hospital cardiac catheterization laboratory.

The new CardioDex thermal femoral artery closure device was used in 25 diagnostic cases and 16 interventional cases. The 100% success rate was obtained for normal or diseased femoral vessels with calcified plaque. According to Dr Shimon Eckhouse, Chairman and founder of CardioDex Ltd., "These very positive results confirm the data we observed in the first single-center clinical trial, that were presented earlier this year. This demonstrated performance of the Cardiodex closure device opens the door to a whole new and long awaited era for femoral arterial access and closure." One of the most exciting features of the device is the extremely short period before patient ambulation, diagnostic patients were ambulated within 2 hours and PCI (Percutaneous Coronary Intervention) patients were ambulated within 4 hours. There were no cases of hematoma or late bleeding, despite the fact that PCI patients were fully anticoagulated with heparin, aspirin and clopidogrel. Neither were there any cases of post procedural discomfort.

Method of action

The mechanism of action of the CardioDex device is based on controlled thermal closure of the arterial puncture site. The device consists of a temporary Nitinol anchor which is delivered via an existing introducer sheath and used to locate the puncture site. ,. The fully controlled heating step is made possible by an integrated battery power unit and a heating system that is inserted over the Nitinol anchor wire on the site of the arteriotomy. Local short heating pulses provide sufficient hemostasis through the cross linking of collagen, leaving no residual material at the puncture site.

Unmet medical need

The market for percutaneous femoral access and vascular closure devices has grown significantly since they were first launched in the early 1990's and is based on a wide range of technologies. While some of the newer closure devices can be used in what was considered to be patients at high risk such as those with PAD (Peripheral Arterial Disease) and smaller caliber arteries, the CardioDex device can be used in all types of patients and situations, including bifurcations, PAD, SFA (superficial femoral arterial) punctures as well as in very thin or obese patients. Whatever the anatomic challenge, the CardioDex device has consistently shown outstanding efficacy, short time to ambulation and reliable closures free of residual materials.

Professor Charles Davidson, Clinical Chief, Cardiology Medical Director, Bluhm Cardiovascular Institute Northwestern Memorial Hospital and CardioDex's Chief medical officer states that:  "Thermal closure of the arterial puncture site has several potential advantages including nothing left behind and the ability to address challenging anatomies.  The initial successful cases we have had demonstrate the promise of this new technology".

About CardioDex

CardioDex (http://www.cardiodex.com) was founded by one of the most renowned medical entrepreneurs in the health and aesthetic medicine arena, Dr. Shimon Eckhouse, a scientist with broad experience in medical devices and medical technology.

CardioDex, Ltd. develops and manufactures an innovative disposable solution for the closure of arterial access sites following endovascular catheterization procedures. The Company also owns a rich intellectual proprietary portfolio and a strong and concrete IP coverage of its current and future technology applications.

Media contact:
Burson-Marsteller
Linda Pavy
Tel. +33-1-41-86-76-26
Tel. +33-6-07-59-43-95
e-mail: linda.pavy@bm.com



'/>"/>
SOURCE CardioDex Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
4. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
5. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
6. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)
7. ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384
8. Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
9. Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan
10. A revolutionary breakthrough in terahertz remote sensing
11. A revolutionary breakthrough in terahertz remote sensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
Breaking Biology Technology:
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):